Clinical trialNCT04983810UnknownPhase 1/PHASE2Interventional

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

SponsorCyclacel Pharmaceuticals, Inc.Enrollment330LymphomaSolid Tumor, Adult

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of fadraciclib administered orally BID. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for which no standard therapy exists.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mark H Kirschbaum, MD
Cyclacel Pharmaceuticals, Inc.
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

South Korea

Seoul National University Hospital
Seoul, South Korea
Recruiting

Spain

Hospital Universitario Vall D'Hebron
Barcelona, Spain
Recruiting

United States

City of Hope
Duarte, California, United States
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fadraciclib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Jul 2021
Primary completion: 30 Apr 2025
Completion: 30 Jun 2025
Last update posted: 25 Jan 2024
Registered enrollment: 330
Registry id: NCT04983810

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.